Improved platelet inhibition with ticagrelor when compared to clopidogrel in peripheral artery disease patients
Journal of Vascular Surgery · 2026
DOI: 10.1016/j.jvs.2025.08.022 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Vascular Surgery, 2026. Verfasst von Mounika Naidu Boya und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Vascular and Endovascular Surgery, Massachusetts General Hospital, Boston, MA. Hauptthemen laut MEDLINE: Ticagrelor, Clopidogrel, Peripheral Arterial Disease, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: NIA NIH HHS, National Institutes of Health, Foundation for the National Institutes of Health.
Abstract (Originalsprache)
BACKGROUND: Clopidogrel and ticagrelor are well-known antiplatelet drugs that inhibit P2Y12 receptors. Although clopidogrel is currently the standard of care for peripheral artery disease (PAD), 25% of patients are known to exhibit drug resistance due to genetic variability. Ticagrelor presents an alternative with reduced susceptibility to genetic variations and has demonstrated superior outcomes in acute coronary syndromes. However, ticagrelor currently lacks a formal indication for PAD management. This study aims to compare the clot strength and platelet function in patients with PAD transitioning from aspirin-clopidogrel to aspirin-ticagrelor using thromboelastography with platelet mapping (TEG-PM). METHODS: Patients with PAD who underwent revascularization surgery at a single tertiary center were enrolled from December 2022 to December 2024. TEG-PM analysis was performed at baseline, 1 week, 1 month, 3 months, and 6 months. Patients who switched from clopidogrel to ticagrelor were included in this study. Consenting patients also underwent VerifyNow testing for clopidogrel resistance. Statistical analysis used descriptive statistics and the Wilcoxon matched-pairs test to compare TEG-PM parameters. RESULTS: In our cohort of 35 patients (mean age 66.49 ± 10.74 years, 65.7% male), significant differences were observed in platelet function parameters. Adenosine diphosphate-mediated maximum amplitude that depicts clot strength was significantly lower with ticagrelor compared with clopidogrel (50.8 mm vs 59.5 mm, P 180). CONCLUSIONS: Ticagrelor demonstrated superior platelet inhibition to clopidogrel in patients with PAD after revascularization. The high prevalence of clopidogrel resistance underscores the potential clinical benefit of ticagrelor for patients with PAD after revascularization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Vascular and Endovascular Surgery, Massachusetts General Hospital, Boston, MA.
- Division of Vascular and Endovascular Surgery, Massachusetts General Hospital, Boston, MA. Electronic address: adua1@mgh.harvard.edu.
Förderung
- NIA NIH HHS
- National Institutes of Health
- Foundation for the National Institutes of Health
Zitieren
APA
Boya, M. N., Cieri, I. F., Rodriguez Alvarez, A. A., Patel, S., & Dua, A. (2026). Improved platelet inhibition with ticagrelor when compared to clopidogrel in peripheral artery disease patients. Journal of Vascular Surgery. https://doi.org/10.1016/j.jvs.2025.08.022
Vancouver
Boya MN, Cieri IF, Rodriguez Alvarez AA, Patel S, Dua A. Improved platelet inhibition with ticagrelor when compared to clopidogrel in peripheral artery disease patients. Journal of Vascular Surgery. 2026. doi:10.1016/j.jvs.2025.08.022
BibTeX
@article{Boya2026,
author = {Boya, Mounika Naidu and Cieri, Isabella F and Rodriguez Alvarez, Adriana Araceli and Patel, Shiv and Dua, Anahita},
title = {Improved platelet inhibition with ticagrelor when compared to clopidogrel in peripheral artery disease patients},
journal = {Journal of Vascular Surgery},
year = {2026},
doi = {10.1016/j.jvs.2025.08.022}
}
EUVIMED